Targets › COQ10
5 programs from 5 companies in 5 trials: 2 Phase 2, 2 Phase 3, 1 Phase 4; Neurology, Cardiovascular, Respiratory; next expected readout Dec 2026.
Open in Phaseline: the race on COQ10, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The Second Affiliated Hospital of Chongqing Medical University | Coenzyme Q10 Mitochondrial electron transport chain cofactor; may reduce oxidative stress and inflammat | COQ10 | Phase 4 | Postoperative Pain | – |
| University of California, San Diego | PharmaNord Bio-Quinone Active CoQ10 Gold 100mg Coenzyme Q10 (ubiquinone) supplementation | COQ10 | Phase 3 | Gulf War Syndrome | Dec 2027 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Idebenone Mitochondrial energy metabolism enhancer; improves cellular energy production through impr | COQ10 | Phase 3 | Migraine Disorders | – |
| Medical College of Wisconsin | MitoQ Mitochondrial-targeted antioxidant (ubiquinone derivative) | COQ10 | Phase 2 | Stroke | Dec 2026 |
| George Washington University | CoQ10 1200 mg Mitochondrial electron transport chain cofactor with antioxidant properties | COQ10 | Phase 2 | Renal Failure | Jun 2027 |
Renal Failure (1) Gulf War Syndrome (1) Migraine Disorders (1) Stroke (1) Postoperative Pain (1)
small molecule (4)
George Washington University (1) University of California, San Diego (1) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) Medical College of Wisconsin (1) The Second Affiliated Hospital of Chongqing Medical University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.